SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Courtesy of Gilead Sciences

358

Gilead Sciences

GILD

U.S.

Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

Looking for leads, investment insights, or competitive intelligence?

CEO

John F. Milligan

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, CA

Years on Global 500 List

3

Employees

9,000

Gilead Sciences is also featured in these fortune lists
Key Financials (Last Fiscal Year)
($ Millions)% change
Revenues ($M)$30,390-6.9%
Profits ($M)$13,501.0-25.4%
Assets ($M)$56,977
Total Stockholder Equity ($M)$18,887
Profit Ratios
Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Gilead's New Cancer Gene Therapy Has Been Approved by the FDA

The price of the drug, which is to be administered just once to each patient, will be $373,000.

Read More →
The Trump White House Gave These Mutual Funds a Big Boost

They're more popular than ever, even though the political winds are against them.

Read More →
The Way We Treat Cancer Will Be Revolutionized As Gene Therapy Comes to the U.S.

FDA approves Novartis treatment that reengineers human cells to kill cancer

Read More →